Expression of type V secretory phospholipase A2 in myocardial remodelling after infarction

Yukio Ishikawa, K. Komiyama, S. Masuda, M. Murakami, Y. Akasaka, K. Ito, Y. Akishima-Fukasawa, M. Kimura, A. Fujimoto, I. Kudo, T. Ishii

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Aims: Secretory phospholipase A2 is associated with ischaemic injury in the human heart, but the distribution of type V secretory phospholipase A2 (sPLA2-V) remains unknown. The significance of sPLA2-V in myocardial infarction was investigated histopathologically. Methods: Sequential changes in the localization of sPLA2-V and its mRNA in myocardial tissues obtained from 30 autopsied hearts were examined by immunohistochemistry and in situ hybridization and compared with those of fibronectin, vascular endothelial growth factor (VEGF), interleukin (IL)-1β, tumour necrosis factor (TNF)-α, and cyclooxygenase-2 (COX-2). Results: No expression of sPLA2-V was observed in normal heart, but it was promptly expressed in wavy myofibres positive for fibronectin just after the onset of infarction. sPLA2-V was subsequently expressed in ischaemic cardiomyocytes around the lesion. The expression decreased at the granulation tissue and disappeared at the chronic stage with scar formation. The distribution of the signal for SPLA2-V mRNA paralleled that of the protein. Ischaemic myocytes around the lesion expressed VEGF, IL-1β, TNF-α and COX-2 at all stages. Conclusions: sPLA2-V production in myocardium is limited to the acute phase of infarction. sPLA2-V may play a dual role, acting both to remove degraded cell-membrane through cooperative activity with COX-2 in necrotic areas and to attack ischaemic myocytes around the lesion via degradation of membrane phospholipids.

Original languageEnglish
Pages (from-to)257-267
Number of pages11
JournalHistopathology
Volume47
Issue number3
DOIs
Publication statusPublished - 2005 Sep
Externally publishedYes

Fingerprint

Secretory Phospholipase A2
Cyclooxygenase 2
Infarction
Interleukin-1
Fibronectins
Muscle Cells
Vascular Endothelial Growth Factor A
Tumor Necrosis Factor-alpha
Messenger RNA
Granulation Tissue
Cardiac Myocytes
Cicatrix
In Situ Hybridization
Phospholipids
Myocardium
Immunohistochemistry
Myocardial Infarction
Cell Membrane
Membranes
Wounds and Injuries

Keywords

  • Cyclooxygenase-2
  • Immunohistochemistry
  • in situ hybridization
  • Myocardial infarction
  • Myocardial remodelling
  • Type V secretory phospholipase A

ASJC Scopus subject areas

  • Anatomy
  • Pathology and Forensic Medicine
  • Cell Biology

Cite this

Ishikawa, Y., Komiyama, K., Masuda, S., Murakami, M., Akasaka, Y., Ito, K., ... Ishii, T. (2005). Expression of type V secretory phospholipase A2 in myocardial remodelling after infarction. Histopathology, 47(3), 257-267. https://doi.org/10.1111/j.1365-2559.2005.02227.x

Expression of type V secretory phospholipase A2 in myocardial remodelling after infarction. / Ishikawa, Yukio; Komiyama, K.; Masuda, S.; Murakami, M.; Akasaka, Y.; Ito, K.; Akishima-Fukasawa, Y.; Kimura, M.; Fujimoto, A.; Kudo, I.; Ishii, T.

In: Histopathology, Vol. 47, No. 3, 09.2005, p. 257-267.

Research output: Contribution to journalArticle

Ishikawa, Y, Komiyama, K, Masuda, S, Murakami, M, Akasaka, Y, Ito, K, Akishima-Fukasawa, Y, Kimura, M, Fujimoto, A, Kudo, I & Ishii, T 2005, 'Expression of type V secretory phospholipase A2 in myocardial remodelling after infarction', Histopathology, vol. 47, no. 3, pp. 257-267. https://doi.org/10.1111/j.1365-2559.2005.02227.x
Ishikawa, Yukio ; Komiyama, K. ; Masuda, S. ; Murakami, M. ; Akasaka, Y. ; Ito, K. ; Akishima-Fukasawa, Y. ; Kimura, M. ; Fujimoto, A. ; Kudo, I. ; Ishii, T. / Expression of type V secretory phospholipase A2 in myocardial remodelling after infarction. In: Histopathology. 2005 ; Vol. 47, No. 3. pp. 257-267.
@article{5129ef1d7ef2444b9e852b3f22c02da7,
title = "Expression of type V secretory phospholipase A2 in myocardial remodelling after infarction",
abstract = "Aims: Secretory phospholipase A2 is associated with ischaemic injury in the human heart, but the distribution of type V secretory phospholipase A2 (sPLA2-V) remains unknown. The significance of sPLA2-V in myocardial infarction was investigated histopathologically. Methods: Sequential changes in the localization of sPLA2-V and its mRNA in myocardial tissues obtained from 30 autopsied hearts were examined by immunohistochemistry and in situ hybridization and compared with those of fibronectin, vascular endothelial growth factor (VEGF), interleukin (IL)-1β, tumour necrosis factor (TNF)-α, and cyclooxygenase-2 (COX-2). Results: No expression of sPLA2-V was observed in normal heart, but it was promptly expressed in wavy myofibres positive for fibronectin just after the onset of infarction. sPLA2-V was subsequently expressed in ischaemic cardiomyocytes around the lesion. The expression decreased at the granulation tissue and disappeared at the chronic stage with scar formation. The distribution of the signal for SPLA2-V mRNA paralleled that of the protein. Ischaemic myocytes around the lesion expressed VEGF, IL-1β, TNF-α and COX-2 at all stages. Conclusions: sPLA2-V production in myocardium is limited to the acute phase of infarction. sPLA2-V may play a dual role, acting both to remove degraded cell-membrane through cooperative activity with COX-2 in necrotic areas and to attack ischaemic myocytes around the lesion via degradation of membrane phospholipids.",
keywords = "Cyclooxygenase-2, Immunohistochemistry, in situ hybridization, Myocardial infarction, Myocardial remodelling, Type V secretory phospholipase A",
author = "Yukio Ishikawa and K. Komiyama and S. Masuda and M. Murakami and Y. Akasaka and K. Ito and Y. Akishima-Fukasawa and M. Kimura and A. Fujimoto and I. Kudo and T. Ishii",
year = "2005",
month = "9",
doi = "10.1111/j.1365-2559.2005.02227.x",
language = "English",
volume = "47",
pages = "257--267",
journal = "Histopathology",
issn = "0309-0167",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Expression of type V secretory phospholipase A2 in myocardial remodelling after infarction

AU - Ishikawa, Yukio

AU - Komiyama, K.

AU - Masuda, S.

AU - Murakami, M.

AU - Akasaka, Y.

AU - Ito, K.

AU - Akishima-Fukasawa, Y.

AU - Kimura, M.

AU - Fujimoto, A.

AU - Kudo, I.

AU - Ishii, T.

PY - 2005/9

Y1 - 2005/9

N2 - Aims: Secretory phospholipase A2 is associated with ischaemic injury in the human heart, but the distribution of type V secretory phospholipase A2 (sPLA2-V) remains unknown. The significance of sPLA2-V in myocardial infarction was investigated histopathologically. Methods: Sequential changes in the localization of sPLA2-V and its mRNA in myocardial tissues obtained from 30 autopsied hearts were examined by immunohistochemistry and in situ hybridization and compared with those of fibronectin, vascular endothelial growth factor (VEGF), interleukin (IL)-1β, tumour necrosis factor (TNF)-α, and cyclooxygenase-2 (COX-2). Results: No expression of sPLA2-V was observed in normal heart, but it was promptly expressed in wavy myofibres positive for fibronectin just after the onset of infarction. sPLA2-V was subsequently expressed in ischaemic cardiomyocytes around the lesion. The expression decreased at the granulation tissue and disappeared at the chronic stage with scar formation. The distribution of the signal for SPLA2-V mRNA paralleled that of the protein. Ischaemic myocytes around the lesion expressed VEGF, IL-1β, TNF-α and COX-2 at all stages. Conclusions: sPLA2-V production in myocardium is limited to the acute phase of infarction. sPLA2-V may play a dual role, acting both to remove degraded cell-membrane through cooperative activity with COX-2 in necrotic areas and to attack ischaemic myocytes around the lesion via degradation of membrane phospholipids.

AB - Aims: Secretory phospholipase A2 is associated with ischaemic injury in the human heart, but the distribution of type V secretory phospholipase A2 (sPLA2-V) remains unknown. The significance of sPLA2-V in myocardial infarction was investigated histopathologically. Methods: Sequential changes in the localization of sPLA2-V and its mRNA in myocardial tissues obtained from 30 autopsied hearts were examined by immunohistochemistry and in situ hybridization and compared with those of fibronectin, vascular endothelial growth factor (VEGF), interleukin (IL)-1β, tumour necrosis factor (TNF)-α, and cyclooxygenase-2 (COX-2). Results: No expression of sPLA2-V was observed in normal heart, but it was promptly expressed in wavy myofibres positive for fibronectin just after the onset of infarction. sPLA2-V was subsequently expressed in ischaemic cardiomyocytes around the lesion. The expression decreased at the granulation tissue and disappeared at the chronic stage with scar formation. The distribution of the signal for SPLA2-V mRNA paralleled that of the protein. Ischaemic myocytes around the lesion expressed VEGF, IL-1β, TNF-α and COX-2 at all stages. Conclusions: sPLA2-V production in myocardium is limited to the acute phase of infarction. sPLA2-V may play a dual role, acting both to remove degraded cell-membrane through cooperative activity with COX-2 in necrotic areas and to attack ischaemic myocytes around the lesion via degradation of membrane phospholipids.

KW - Cyclooxygenase-2

KW - Immunohistochemistry

KW - in situ hybridization

KW - Myocardial infarction

KW - Myocardial remodelling

KW - Type V secretory phospholipase A

UR - http://www.scopus.com/inward/record.url?scp=24144434707&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=24144434707&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2559.2005.02227.x

DO - 10.1111/j.1365-2559.2005.02227.x

M3 - Article

C2 - 16115226

AN - SCOPUS:24144434707

VL - 47

SP - 257

EP - 267

JO - Histopathology

JF - Histopathology

SN - 0309-0167

IS - 3

ER -